JP2016500255A - ハイスループットなレセプター：リガンド同定の方法 - Google Patents

ハイスループットなレセプター：リガンド同定の方法 Download PDF

Info

Publication number
JP2016500255A
JP2016500255A JP2015545835A JP2015545835A JP2016500255A JP 2016500255 A JP2016500255 A JP 2016500255A JP 2015545835 A JP2015545835 A JP 2015545835A JP 2015545835 A JP2015545835 A JP 2015545835A JP 2016500255 A JP2016500255 A JP 2016500255A
Authority
JP
Japan
Prior art keywords
protein
cell
cells
peptide
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015545835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500255A5 (enExample
Inventor
スティーブン シー． アルモ
スティーブン シー． アルモ
ロナルド ディー． サード ザイデル
ロナルド ディー． サード ザイデル
ブランダン エス． ヒルリッチ
ブランダン エス． ヒルリッチ
サラ シー． ギャレット−トムソン
サラ シー． ギャレット−トムソン
ジェイムズ ディー． ラブ
ジェイムズ ディー． ラブ
Original Assignee
アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ
アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ, アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ filed Critical アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ
Publication of JP2016500255A publication Critical patent/JP2016500255A/ja
Publication of JP2016500255A5 publication Critical patent/JP2016500255A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
JP2015545835A 2012-12-11 2013-12-05 ハイスループットなレセプター：リガンド同定の方法 Ceased JP2016500255A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261735791P 2012-12-11 2012-12-11
US61/735,791 2012-12-11
US201361833588P 2013-06-11 2013-06-11
US61/833,588 2013-06-11
PCT/US2013/073275 WO2014093118A1 (en) 2012-12-11 2013-12-05 Methods for high throughput receptor:ligand identification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019200491A Division JP7128792B2 (ja) 2012-12-11 2019-11-05 ハイスループットなレセプター：リガンド同定の方法

Publications (2)

Publication Number Publication Date
JP2016500255A true JP2016500255A (ja) 2016-01-12
JP2016500255A5 JP2016500255A5 (enExample) 2017-01-19

Family

ID=50934838

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545835A Ceased JP2016500255A (ja) 2012-12-11 2013-12-05 ハイスループットなレセプター：リガンド同定の方法
JP2019200491A Active JP7128792B2 (ja) 2012-12-11 2019-11-05 ハイスループットなレセプター：リガンド同定の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019200491A Active JP7128792B2 (ja) 2012-12-11 2019-11-05 ハイスループットなレセプター：リガンド同定の方法

Country Status (11)

Country Link
US (2) US10048271B2 (enExample)
EP (2) EP2931949B1 (enExample)
JP (2) JP2016500255A (enExample)
KR (1) KR102208505B1 (enExample)
CN (2) CN105121715B (enExample)
AU (2) AU2013359907B2 (enExample)
BR (1) BR112015013557B1 (enExample)
CA (1) CA2894511C (enExample)
IL (2) IL239096B (enExample)
SG (2) SG11201504558TA (enExample)
WO (1) WO2014093118A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018087811A (ja) * 2016-11-24 2018-06-07 国立研究開発法人物質・材料研究機構 細胞表面に存在する分子の結合による細胞間相互作用を計測する方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121715B (zh) 2012-12-11 2018-10-26 艾伯特叶史瓦大学爱因斯坦医学院 高通量受体:配体鉴定方法
CA2954360C (en) * 2014-07-07 2022-11-22 Johan ELF Phenotypic characterization and in situ genotyping of a library of genetically different cells
CN109475628A (zh) 2016-05-18 2019-03-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CA3022331A1 (en) * 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
WO2018111941A1 (en) * 2016-12-12 2018-06-21 13.8, Inc. Compositions of high affinity reagents and methods of use thereof
AU2017379900B2 (en) 2016-12-22 2024-12-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4143221A1 (en) * 2020-04-30 2023-03-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Pd-l1 variants with improved affinity towards pd-1
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524506A (ja) * 2007-04-27 2010-07-22 ダウ グローバル テクノロジーズ インコーポレイティド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
JP3816959B2 (ja) 1997-02-13 2006-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肝細胞癌の予防および処置
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US20030007978A1 (en) 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6696304B1 (en) * 1999-02-24 2004-02-24 Luminex Corporation Particulate solid phase immobilized protein quantitation
US7446189B1 (en) 1999-04-30 2008-11-04 Institut De Recherches Cliniques De Montreal Nucleic acids encoding mutant human CD80 and compositions comprising the same
US20020006664A1 (en) 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
WO2001090747A2 (en) 2000-05-25 2001-11-29 Sunol Molecular Corporation Modulation of t-cell receptor interactions
US20020122820A1 (en) 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
US6800748B2 (en) 2001-01-25 2004-10-05 Large Scale Biology Corporation Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector
CA2440773A1 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules
AU2002309865A1 (en) * 2001-05-15 2002-11-25 University Of Medicine & Dentistry Of New Jersey Methods for analyzing interactions between proteins in live and intact cells
CN1533432A (zh) 2001-06-04 2004-09-29 MLʵ���ҹ������޹�˾ 高水平、大规模生产重组蛋白的组合体和方法
US20030017134A1 (en) 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2002368044A1 (en) 2001-06-22 2004-04-19 Maxygen, Inc. Co-stimulatory molecules
WO2003006632A2 (en) 2001-07-12 2003-01-23 Canvac Methods and compisitions for activation human t cells in vitro
WO2003040307A2 (en) 2001-07-27 2003-05-15 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
US20070148162A1 (en) 2003-02-27 2007-06-28 Ranjit Bhardwaj Molecule which binds cd80 and cd86
AU2003901876A0 (en) 2003-04-17 2003-05-08 The Macfarlane Burnet Institute For Medical Research And Public Health Viral vector
US20050042641A1 (en) 2003-05-27 2005-02-24 Cold Spring Harbor Laboratory In vivo high throughput selection of RNAi probes
US7470513B2 (en) 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
AU2005227263A1 (en) 2004-03-05 2005-10-06 Novartis Vaccines And Diagnostics, Inc. In vitro test system for predicting patient tolerability of therapeutic agents
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR20080082628A (ko) * 2005-11-10 2008-09-11 리셉터 바이오로직스 인크 수용체 및 리간드 이소형태의 제조 방법
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
ES2549128T3 (es) 2006-05-19 2015-10-23 Technion Research And Development Foundation Ltd. Proteínas de fusión, usos de las mismas y procesos para producir las mismas
EP1889851A1 (en) 2006-08-18 2008-02-20 Charite Universitätsmedizin-Berlin PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
US8992937B2 (en) 2006-08-28 2015-03-31 Washington University Disulfide trap MHC class I molecules and uses therefor
CN101573448B (zh) 2006-12-28 2012-07-11 株式会社癌免疫研究所 Hla-a*1101限制的wt1肽及含有其的药物组合物
EP2129389B1 (en) 2007-02-15 2014-10-08 MannKind Corporation A method for enhancing t cell response
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
US8926961B2 (en) 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
CN101418309B (zh) 2007-10-23 2011-05-04 中国农业科学院上海兽医研究所 柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
EP2184070A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US20120178703A1 (en) 2009-06-25 2012-07-12 Commisariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
NZ599405A (en) * 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
CN105017429B (zh) * 2010-09-21 2021-04-06 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
ES2667864T3 (es) 2011-06-22 2018-05-14 F. Hoffmann-La Roche Ag Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I
EP2726101B1 (en) 2011-06-30 2018-08-08 Genzyme Corporation Inhibitors of t-cell activation
WO2013030620A2 (de) 2011-08-30 2013-03-07 Jacobs University Bremen Ggmbh Gen codiert für ein mhc-klasse-i-molekül, plasmid, expressionssystem protein, multimer, reagenz und kit zum analysieren einer t-zellen-frequenz
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
EP2785375B1 (en) * 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
WO2013116656A1 (en) 2012-02-03 2013-08-08 Emory University Immunostimulatory compositions, particles, and uses related thereto
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
BR112015011111A2 (pt) 2012-11-30 2017-11-14 Roche Glycart Ag proteína multifuncional e formulação farmacêutica
CN105121715B (zh) 2012-12-11 2018-10-26 艾伯特叶史瓦大学爱因斯坦医学院 高通量受体:配体鉴定方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
WO2014157692A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
SG11201605632SA (en) 2014-01-21 2016-08-30 Einstein Coll Med Cellular platform for rapid and comprehensive t-cell immunomonitoring
US20160152725A1 (en) 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
EP3112378B1 (en) 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
SG10202006338UA (en) 2014-06-18 2020-08-28 Albert Einstein College Medicine Inc Syntac polypeptides and uses thereof
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
DK3172227T3 (da) 2014-07-21 2019-12-02 Delinia Inc Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
AU2015301753B2 (en) 2014-08-12 2021-04-08 Massachusetts Institute Of Technology Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
AU2015308527C1 (en) 2014-08-29 2021-07-15 F. Hoffmann-La Roche Ag Combination therapy of tumor-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US20180221503A1 (en) 2015-07-31 2018-08-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
CN106565836B (zh) 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
EP3423108A4 (en) 2016-03-02 2019-10-02 Cue Biopharma, Inc. T CELL MODULATING MULTIPLE POLYPEPTIDES AND METHOD OF USE THEREOF
CA3014466A1 (en) 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240115933A (ko) 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CA3022331A1 (en) 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
WO2019051126A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524506A (ja) * 2007-04-27 2010-07-22 ダウ グローバル テクノロジーズ インコーポレイティド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANAL. BIOCHEM., vol. 420, no. 2, JPN6017043123, January 2012 (2012-01-01), pages 127 - 138, ISSN: 0003908599 *
BIOTECHNOL. PROG., vol. 25, no. 3, JPN6018042512, 2009, pages 774 - 783, ISSN: 0003908600 *
MOL. CANCER THER., vol. 4, no. 5, JPN6018042514, 2005, pages 806 - 813, ISSN: 0003908602 *
NAT. BIOTECHNOL., vol. 30, no. 6, JPN6017043119, June 2012 (2012-06-01), pages 543 - 548, ISSN: 0003908598 *
NATURE, vol. 411, no. 6833, JPN6017043125, 2001, pages 107 - 110, ISSN: 0003908603 *
PROC. NATL. ACAD. SCI. U.S.A., vol. 108, no. 51, JPN6018042513, 2011, pages 20455 - 20460, ISSN: 0003908601 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018087811A (ja) * 2016-11-24 2018-06-07 国立研究開発法人物質・材料研究機構 細胞表面に存在する分子の結合による細胞間相互作用を計測する方法
JP7019171B2 (ja) 2016-11-24 2022-02-15 国立研究開発法人物質・材料研究機構 細胞表面に存在する分子の結合による細胞間相互作用を計測する方法

Also Published As

Publication number Publication date
CN105121715B (zh) 2018-10-26
US11226339B2 (en) 2022-01-18
US20160011204A1 (en) 2016-01-14
EP2931949A4 (en) 2016-07-27
HK1218144A1 (zh) 2017-02-03
SG10201808463RA (en) 2018-11-29
IL262785A (en) 2018-12-31
AU2018201812A1 (en) 2018-04-05
CA2894511A1 (en) 2014-06-19
AU2013359907A1 (en) 2015-06-18
EP3640375A3 (en) 2020-07-29
CA2894511C (en) 2021-12-07
KR102208505B1 (ko) 2021-01-27
AU2018201812B2 (en) 2020-09-10
IL239096B (en) 2019-03-31
EP2931949B1 (en) 2019-09-18
JP7128792B2 (ja) 2022-08-31
EP3640375A2 (en) 2020-04-22
KR20150094674A (ko) 2015-08-19
JP2020043860A (ja) 2020-03-26
IL239096A0 (en) 2015-07-30
EP2931949A1 (en) 2015-10-21
BR112015013557A2 (pt) 2020-01-14
BR112015013557B1 (pt) 2021-12-14
IL262785B (en) 2020-04-30
SG11201504558TA (en) 2015-07-30
CN109324190A (zh) 2019-02-12
WO2014093118A1 (en) 2014-06-19
CN105121715A (zh) 2015-12-02
US10048271B2 (en) 2018-08-14
US20200011875A1 (en) 2020-01-09
AU2013359907B2 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
JP7128792B2 (ja) ハイスループットなレセプター：リガンド同定の方法
Chong et al. Pooled extracellular receptor-ligand interaction screening using CRISPR activation
Ramani et al. A secreted protein microarray platform for extracellular protein interaction discovery
Sims et al. MHC–peptide tetramers for the analysis of antigen-specific T cells
US20040248205A1 (en) Major histocompatibility complex (MHC)-peptide arrays
AU2020270834B2 (en) Methods and systems for screening using microcapillary arrays
TW201818958A (zh) 製造和使用可溶性主要組織相容性複合體（ｍｈｃ）分子類之方法
US20220154174A1 (en) Method of Selecting for Antibodies
EP4190951A1 (en) Highly parallel assays for simultaneous identification of antibody sequences and binding partners
CA2977436C (en) Antibody detection method and system
Deering et al. Rapid TCR: Epitope Ranker (RAPTER): a primary human T cell reactivity screening assay pairing epitope and TCR at single cell resolution
Jiang et al. Identification of leucocyte surface protein interactions by high‐throughput screening with multivalent reagents
Anaya et al. A multiplex extracellular interactome screening method employing high-avidity nanoparticles
US20250163406A1 (en) Methods for generating nucleic acid encoded protein libraries and uses thereof
Tom et al. Baculovirus display for discovery of low-affinity extracellular receptor–ligand interactions using protein microarrays
HK1218144B (zh) 高通量受体:配体鉴定方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161201

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170814

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190423

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191003

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20200122